These forward-looking statements speak only as of the date hereof. The Merger Agreement also provides customary termination rights to each of the parties. Company BackgroundWe were incorporated in Delaware as Calderome, Inc. in August 2006. Calderome operated as an incubator until early 2008. Diagnostic surgery is risky, expensive and may not be viable for some patients. The Afirma classifier is included in most leading medical guidelines. The Prosigna test achieved Medicare coverage in 2015. In 2021, Prosigna's rate will decrease by 15% to approximately $2,134. Failure to meet the terms of the safe harbor does not render an arrangement illegal. Some of these items are unique to these suppliers and vendors. As we introduce any new test, we may experience supply issues as we ramp test volume. A specific CPT code (81554) was assigned to Envisia, effective January 1, 2021. We may experience limits on our revenue if patients decide not to use our tests. We are also required to maintain state licenses to conduct testing in our laboratories. We have received approval for the Afirma, Percepta and Envisia tests. Due to how we recognize revenue, our quarterly operating results are likely to fluctuate. We believe that PAMA and its implementing regulations are generally favorable to us. In 2016, the FDA announced that it would not be finalizing the guidance. We use standard industry billing codes, known as CPT codes, to bill for cytopathology. We may not be able to obtain these licenses on acceptable terms, if at all.